Literature DB >> 35111598

Dual-source dual-energy computed tomography-derived quantitative parameters combined with machine learning for the differential diagnosis of benign and malignant thyroid nodules.

Liling Jiang1,2, Daihong Liu1,2, Ling Long1,2, Jiao Chen1,2, Xiaosong Lan1,2, Jiuquan Zhang1,2.   

Abstract

BACKGROUND: This study aimed to investigate the ability of quantitative parameter-derived dual-source dual-energy computed tomography (DS-DECT) combined with machine learning to distinguish between benign and malignant thyroid nodules.
METHODS: Patients with thyroid nodules and pathological surgical results who underwent preoperative DS-DECT were selected. Quantitative parameter-derived DS-DECT was applied to classify benign and malignant nodules. Then, machine learning and binary logistic regression analysis models were constructed using the DS-DECT quantitative parameters to distinguish between benign and malignant nodules. The receiver operating characteristic curve was used to assess the diagnostic performance. The DeLong test was used to compare the diagnostic efficacy.
RESULTS: One hundred and thirty patients with 139 confirmed thyroid nodules were involved in the study. The malignant group had a significantly higher iodine concentrationnodule (arterial phase) (P=0.001), normalized iodine concentration (arterial phase) (P=0.002), iodine concentration difference (P<0.001), spectral curve slope (nonenhancement) (P=0.007), spectral curve slope (arterial phase) (P=0.001), effective atomic number (nonenhancement) (P<0.001), and effective atomic number (arterial phase) (P=0.039) than the benign group. The binary logistic regression analysis model had an AUC (area under the curve) of 0.76, a sensitivity of 0.821, and a specificity of 0.667. The machine learning model had an AUC of 0.86, a sensitivity of 0.822, specificity of 0.791 in the training cohort, an AUC of 0.84, a sensitivity of 0.727, and specificity of 0.750 in the testing cohort.
CONCLUSIONS: Multiple quantitative parameters of DS-DECT combined with machine learning could differentiate between benign and malignant thyroid nodules. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Thyroid nodule; dual-source dual-energy computed tomography (DS-DECT); machine learning

Year:  2022        PMID: 35111598      PMCID: PMC8739151          DOI: 10.21037/qims-21-501

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  45 in total

Review 1.  Incidental thyroid nodules on chest CT: Review of the literature and management suggestions.

Authors:  Sameer Ahmed; Karen M Horton; R Brooke Jeffrey; Sheila Sheth; Elliot K Fishman
Journal:  AJR Am J Roentgenol       Date:  2010-11       Impact factor: 3.959

2.  A new method to measure electron density and effective atomic number using dual-energy CT images.

Authors:  Luis Isaac Ramos Garcia; José Fernando Pérez Azorin; Julio F Almansa
Journal:  Phys Med Biol       Date:  2015-12-09       Impact factor: 3.609

3.  Clinical routine use of virtual monochromatic datasets based on spectral CT in patients with hypervascularized abdominal tumors - evaluation of effectiveness and efficiency.

Authors:  Georg Böning; Felix Feldhaus; Sebastian Adelt; Johannes Kahn; Uli Fehrenbach; Florian Streitparth
Journal:  Acta Radiol       Date:  2018-06-27       Impact factor: 1.990

4.  Correlation study between dual source CT perfusion imaging and the microvascular composition of solitary pulmonary nodules.

Authors:  Meng Wang; Bangguo Li; Hui Sun; Tingting Huang; Xuemei Zhang; Kaiyuan Jin; Feng Wang; Xianli Luo
Journal:  Lung Cancer       Date:  2019-02-16       Impact factor: 5.705

5.  Thyroid-stimulating hormone levels within the reference range are associated with serum lipid profiles independent of thyroid hormones.

Authors:  Furong Wang; Yinyin Tan; Chenggang Wang; Xu Zhang; Yuanfei Zhao; Xinhong Song; Bingchang Zhang; Qingbo Guan; Jin Xu; Ji Zhang; Dongzhi Zhang; Haiyan Lin; Chunxiao Yu; Jiajun Zhao
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

6.  Double Low-Dose Dual-Energy Liver CT in Patients at High-Risk of HCC: A Prospective, Randomized, Single-Center Study.

Authors:  Jeong Hee Yoon; Won Chang; Eun Sun Lee; Sang Min Lee; Jeong Min Lee
Journal:  Invest Radiol       Date:  2020-06       Impact factor: 6.016

7.  Papillary thyroid cancer: dual-energy spectral CT quantitative parameters for preoperative diagnosis of metastasis to the cervical lymph nodes.

Authors:  Xuewen Liu; Dian Ouyang; Hui Li; Rong Zhang; Yanchun Lv; Ankui Yang; Chuanmiao Xie
Journal:  Radiology       Date:  2014-12-17       Impact factor: 11.105

8.  Optimal Virtual Monochromatic Images for Evaluation of Normal Tissues and Head and Neck Cancer Using Dual-Energy CT.

Authors:  S Lam; R Gupta; M Levental; E Yu; H D Curtin; R Forghani
Journal:  AJNR Am J Neuroradiol       Date:  2015-05-28       Impact factor: 3.825

9.  Dual-energy CT quantitative parameters for evaluating Immunohistochemical biomarkers of invasive breast cancer.

Authors:  Xiaoxia Wang; Daihong Liu; Xiangfei Zeng; Shixi Jiang; Lan Li; Tao Yu; Jiuquan Zhang
Journal:  Cancer Imaging       Date:  2021-01-07       Impact factor: 3.909

10.  Application of dual-source CT perfusion imaging and MRI for the diagnosis of primary liver cancer.

Authors:  Dongwen Zhang; Aixia Xu
Journal:  Oncol Lett       Date:  2017-05-15       Impact factor: 2.967

View more
  2 in total

1.  Parameters of dual-energy CT for the differential diagnosis of thyroid nodules and the indirect prediction of lymph node metastasis in thyroid carcinoma: a retrospective diagnostic study.

Authors:  Fu Li; Fuling Huang; Chenmin Liu; Denghua Pan; Xiaoqi Tang; Yan Wen; Zhibai Chen; Yuhong Qin; Junqiang Chen
Journal:  Gland Surg       Date:  2022-05

2.  Diagnostic Effectiveness of Dual Source Dual Energy Computed Tomography for Benign and Malignant Thyroid Nodules.

Authors:  Tong Zhu; Kanglin Xie; Chongxiao Wang; Linkui Wang; Wei Liu; Faping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-17       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.